drugset / Trial / NCT02513563

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

NCT02513563

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.

Timeline

Start
2015-10-13
Primary completion
2022-11-27
Completion
2023-11-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Adavosertib Small molecule 225 mg
Background Carboplatin Small molecule
Background Paclitaxel Small molecule 175 mg/m2

Indications